Pune, India -- (SBWIRE) -- 04/30/2019 -- Erectile Dysfunction Drugs Market report provides the latest market data along with industry future trends, which keeps tracking of users driving revenue growth rate of erectile dysfunction drugs Market by drug (sildenafil (viagra), tadalafil (cialis), vardenafil (levitra,staxyn), avanafil (stendra), muse suppository (alprostadil)), mode of administration (oral, topical, injections), end-user (hospital pharmacies, retail pharmacies, and online pharmacies) market status and outlook of global and major regions, from manufacturers, and end industries.

For More Details Get FREE Sample Pages of this Research Report@ https://www.infiniumglobalresearch.com/reports/sample-request/1967

As this report is expected to help key players among the erectile dysfunction drugs market it includes the five years Industry analysis and the 6 years annual forecast from 2018 to 2024. Some of the prominent participants in the global erectile dysfunction drugs market are Pfizer Inc., Bayer AG, Eli Lily & Co., DONG–A PHARM, Apricus Biosciences Inc., Vivus, Inc., Meda AB, SK Chemicals, Cristalia Produtos Quimicos Farmaceuticos Ltda., and Teva Pharmaceutical Industries Ltd.

Erectile dysfunction affects millions of men all over the world. The erectile dysfunction drugs are extensively used and scientifically proven to treat ED. They are a safe and effective way to cure erectile dysfunction. These drugs improve blood supply to the penis and produce an erection sufficient to initiate and complete intercourse. Pfizer Inc., Bayer AG, Eli Lily & Co., DONG–A PHARM, Apricus Biosciences Inc., Vivus, Inc., Meda AB, SK Chemicals, Cristalia Produtos Quimicos Farmaceuticos Ltda., and Teva Pharmaceutical Industries Ltd. are the major players in the erectile dysfunction drugs market are concentrating on the development of new drugs. In 2018, iX Biopharma Ltd. has received the approval for a sildenafil drug SILCAP delivered using an oral capsule for the treatment of male erectile dysfunction by Therapeutic Goods Administration ("TGA"), the regulatory authority in Australia.

Increasing Aging Population and Stressful Lifestyle to Drive the Growth of the Erectile Dysfunction Drugs Market

The growing prevalence of erectile dysfunction owing to the increase in levels of stress, hypertension, heart diseases, and obesity is driving the growth of the erectile dysfunction drugs market. The growing elderly population contributes to the growth of erectile dysfunction drugs market. The shifting lifestyle trends such as unhealthy diet, physical inactivity, cigarette smoking, and harmful use of alcohol are the major factors responsible for the increasing occurrences of erectile dysfunction. The rising consciousness about such medical conditions and high rate of chronic diseases will increase the demand for erectile dysfunction drugs over the forecast period.

Need Assistance? Send an Enquiry@ https://www.infiniumglobalresearch.com/reports/enquiry/1967

Sildenafil Drug to Dominate the Dysfunction Drug Market

The report on erectile dysfunction drugs market is bifurcated into drug, mode of administration, and end-user. The drugs segment include sildenafil (viagra), tadalafil (cialis), vardenafil (levitra,staxyn), avanafil (stendra), muse suppository (alprostadil), and others drugs. Among these drugs, sildenafil holds the maximum market share in the erectile dysfunction drug market as it is widely used and prescribed by doctors for more than 64 million men worldwide. In addition, the ongoing developments in drug delivery techniques drive the growth of the market.

North America To Hold the Dominant Share in the Erectile Dysfunction Drug Market

North America holds the largest share in the erectile dysfunction drug market. The rising prevalence of erectile dysfunction in the North America region owing to the stressful lifestyle and growing awareness about the ED drugs for curing erectile dysfunction drives the growth of erectile dysfunction drug market in this region. The expiry of patents of several erectile dysfunction drugs is anticipated to drive the growth of the North America dysfunction drug market over the forecast period. Moreover, people in the North America region have high capacity in healthcare expenditure continues to be an added incentive for the growth of erectile dysfunction drug market. Asia-Pacific is the fastest growing in the erectile dysfunction drug market. The rise in the elderly population and growing awareness about erectile dysfunction in the Asia Pacific region drives the growth of erectile dysfunction drug market in this region.

Read Detailed Index of full Research Study@ https://www.infiniumglobalresearch.com/healthcare-medical-devices/global-erectile-dysfunction-drugs-market

Reasons to Buy this Report:

- Comprehensive analysis of global as well as regional markets of the erectile dysfunction drugs.

- Complete coverage of all the product type and applications segments to analyze the trends, developments, and forecast of market size up to 2024.

- Comprehensive analysis of the companies operating in this market. The company profile includes analysis of product portfolio, revenue, SWOT analysis and the latest developments of the company.

- Infinium Global Research- Growth Matrix presents the analysis of the product segments and geographies that market players should focus to invest, consolidate, expand and/or diversify.